Amlodipine/fimasartan - Boryung Pharmaceutical
Alternative Names: BKC-002; Dukarb; Fimasartan/amlodipineLatest Information Update: 30 Oct 2021
At a glance
- Originator Boryung Pharmaceutical
- Class Antihypertensives; Dihydropyridines; Pyrimidinones; Small molecules
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P-450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Essential hypertension
Most Recent Events
- 01 Jun 2018 Chemical structure information added
- 15 May 2018 Launched for Essential hypertension in South Korea (PO) before May 2018
- 15 Dec 2017 Boryung Pharmaceutical initiates a phase I trial (In volunteers) in South Korea (NCT03390465)